参考文献/References:
[1]International Diabetes Federation. IDF Diabetes Atlas [EB/OL].http://www.daibetes atlas.org/resources/2017-atlas.html.2017.
[2]中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2017年版）[J].中国糖尿病杂志,2018,10(1):4-67.
[3]Lago RM,Singh PP,Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones:a meta-analysis of randomised clinical trials[J].Lancet,2007,370(9593):1129-1136.
[4] US Department of Health and Human Services Food and Drug Administration. Guidance for Industry. Diabetes Mellitus‐Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes[EB/OL]. 2008. Available at www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf (accessed October 8, 2018).
[5]Usman MS,Siddiqi TJ,Memon MM,et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes:a systematic review and meta-analysis[J].Eur J Prev Cardiol,2018,25(5):495-502.
[6]Madan Paramasivan A,Purushothaman A,Desouza C. Implications of the CANVAS Study in reducing cardiovascular outcomes[J].Curr Diab Rep,2018,18(12):142.
[7]Skelley JW,Carter BS,Roberts MZ. Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes[J].Vasc Health Risk Manag,2018,14:419-428.
[8]纪立农,郭立新,郭晓慧,等. 钠-葡萄糖共转运蛋白2（SGLT-2）抑制剂临床合理应用中国专家建议[J].中国糖尿病杂志,2016,10(12):865-870.
[9]Carbone S,Dixon DL. The CANVAS Program:implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus[J].Cardiovasc Diabetol,2019,18(1):64.
[10]Jakher H,Chang TI,Tan M,et al. Canagliflozin review-safety and efficacy profile in patients with T2DM[J].Diabetes Metab Syndr Obes,2019,12:209-215.
[11]Stenl?f K,Cefalu WT,Kim KA,et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise[J].Diabetes Obes Metab,2013,15(4):372-382.
[12]Pfeifer M,Townsend RR,Davies MJ,et al. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor,on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus:a post hoc analysis[J].Cardiovasc Diabetol,2017,16(1):29.
[13]Chen G,McAlister FA,Walker RL,et al. Cardiovascular outcomes in Framingham participants with diabetes:the importance of blood pressure[J].Hypertension,2011,57(5):891-897.
[14]Townsend RR,Machin I,Ren J,et al. Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension[J]. J Clin Hypertens,2016,18(1):43-52.
[15]Weir MR,Januszewicz A,Gilbert RE,et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus[J].J Clin Hypertens (Greenwich),2014,16(12):875-882.
[16] Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J].N Engl J Med,2017,377:644-657.
[17]Perkovic V,Jardine MJ,Neal B,et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J].N Engl J Med,2019,380(24):2295-2306.
[18]Sano M,Takei M,Shiraishi Y,et al. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys[J].J Clin Med Res,2016,8(12):844-847.
[19]Radholm K,Figtree G,Perkovic V,et al. Canagliflozin and heart failure in type 2 diabetes mellitus [J].Circulation,2018,138(5):458-468.
[20]Figtree GA,R?dholm K,Barrett TD,et al. Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus[J].Circulation,2019,139(22):2591-2593.
[21]Matsutani D,Sakamoto M,Kayama Y,et al. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes[J].Cardiovasc Diabetol,2018,17()1:73.
[22]Lim VG,Bell RM,Arjun S,et al. SGLT2 inhibitor,canagliflozin,attenuates myocardial infarction in the diabetic and nondiabetic heart[J].JACC Basic Transl Sci,2019,4(1):15-26.
[23]Sezai A,Sekino H,Unosawa S,et al. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes[J].Cardiovasc Diabetol,2019,18(1):76.
[24]Fralick M,Kim SC,Schneeweiss S,et al. Fracture risk after initiation of use of canagliflozin:a cohort study[J].Ann Intern Med,2019,170(3):155-163.
[25]Yuan Z,DeFalco FJ,Ryan PB,et al. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA:a retrospective cohort study[J].Diabetes Obes Metab,2018,20(3):582-589.
[26]Qiu R,Balis D,Xie J,et al. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes:a pooled analysis[J].Curr Med Res Opin,2017,33(3):553-562.
[27]Fleming JW,Fleming LW,Davis CS. Fixed-dose combinations in type 2 diabetes —role of the canagliflozin metformin combination[J].Diabetes Metab Syndr Obes,2015,8:287-294.
相似文献/References:
[1]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(3):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[2]李嘉仪 黄龙祥 罗素新.钠-葡萄糖协同转运蛋白-2抑制剂在心血管疾病中的研究进展[J].心血管病学进展,2019,(9):1245.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.015]
LI JiayiHUANG LongxiangLUO Suxin.SGLT-2 Inhibitors in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(3):1245.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.015]
[3]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(3):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[4]史云聪 郭艺芳.2型糖尿病和动脉粥样硬化性心血管疾病的关系[J].心血管病学进展,2020,(5):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
SHI Yuncong,GUO Yifang.Relationship Between Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(3):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
[5]毛玉琳 何胜虎.2型糖尿病和慢性心力衰竭[J].心血管病学进展,2020,(5):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
MAO Yulin,HE Shenghu.Type 2 Diabetes Mellitus and Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(3):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
[6]吴易航 张宇辉 张健.SGLT2 i恩格列净对2型糖尿病患者心脏保护作用的研究进展[J].心血管病学进展,2020,(8):787.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.001]
WU Yihang,ZHANG Yuhui,ZHANG Jian.Progresses on the Cardiovascular Protection of SGLT2 Inhibitor Empagliflozin in Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(3):787.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.001]
[7]和丽丽 左庆娟 张国瑞 郭艺芳.钠-葡萄糖协同转运蛋白2抑制剂使心力衰竭获益的作用机制[J].心血管病学进展,2020,(9):954.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.017]
HE Lili,ZUO Qingjuan,ZHANG Guorui,et al.Mechanism of Benefit of Sodium-glucose Co-transporter 2 Inhibitors in Heart Failure[J].Advances in Cardiovascular Diseases,2020,(3):954.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.017]
[8]李爽 梁春晓 方鑫 刘莹 余建群.心包内脂肪容积对糖尿病及非糖尿病患者冠状动脉粥样硬化影响的CT评价[J].心血管病学进展,2020,(9):972.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.021]
LI Shuang,LIANG Chunxiao,FANG Xin,et al.Effect of Epicardial Adipose Tissue Volume by CCTA on Coronary Atherosclerosis in Patients with or without Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(3):972.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.021]
[9]王佳玲 叶建荣.2型糖尿病弱化远端缺血预处理的心肌保护作用[J].心血管病学进展,2021,(1):56.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2021.1.000]
WANG Jialing,YE Jianrong.Cardioprotection of Type 2 Diabetes Mellitus with Weakened Remote Ischemic Preconditioning[J].Advances in Cardiovascular Diseases,2021,(3):56.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2021.1.000]
[10].钠-葡萄糖协同转运蛋白2抑制剂获益的研究进展及指南推荐050011；.河北省人民医院老年心血管内科，河北 石家庄 050051）[J].心血管病学进展,2021,(3):252.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.015]
Cardiology Department,The Third Hospital of Shijiazhuang City Affiliated to Hebei Medical University,Shijiazhuang 000,et al.Research Progress and Guideline Recommendations of Cardiovascular Benefits of SGLT-2 Inhibitors[J].Advances in Cardiovascular Diseases,2021,(3):252.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.015]
[11]耿肖囡 肖东斌 魏鑫 惠学志.达格列净对心血管疾病的预防保护机制[J].心血管病学进展,2019,(8):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
GENG Xiaonan,XIAO Dongbin,WEI xin,et al.Preventive and Protective Mechanism of Dagliflozin for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
[12]辛玉晶,刘昊凌.钠-葡萄糖协同转运蛋白２抑制剂与2型糖尿病心血管危险因素的研究进展[J].心血管病学进展,2020,(3):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
XIN Yujing,LIU Haoling.SGLT-2 Inhibitors and Cardiovascular Risk Factors in Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(3):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
[13]张阳扬 尹德录.新型降糖药物在心力衰竭中的应用前[J].心血管病学进展,2020,(6):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
ZHANG Yangyang,YIN Delu.Prospect of New Glucose-lowering Drugs in Heart Failure[J].Advances in Cardiovascular Diseases,2020,(3):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
[14]张欣 郭艺芳.钠-葡萄糖协同转运蛋白2抑制剂相关心血管益处的可能潜在机制[J].心血管病学进展,2020,(9):903.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.004]
ZHANG Xin,GUO Yifang.Potential Mechanisms of Sodium-glucose Co-transporter 2 Inhibitor-related Cardiovascular Benefits[J].Advances in Cardiovascular Diseases,2020,(3):903.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.004]